Loading...
Allergy & Immunology Billing Services
Qualigenix bills allergy testing, allergen immunotherapy, pulmonary function testing, and biologic drugs for allergy and immunology practices in 48 states. Our coders count every skin test, track 95165 doses against each payer's rules, and check J-code units before a drug claim goes out.
What Does Allergy and Immunology Billing Involve?
Allergy and immunology billing covers three code families that pay by count: skin tests billed one unit per test, immunotherapy extract billed by dose (Medicare counts a dose as 1 cc), and biologic drugs billed by J-code units with a JW or JZ modifier. Qualigenix codes all three and works denials to resolution, with a 98.2% first-pass clean claim rate on first submission. Get a free billing audit at 786-259-0231.
01
Skin Test Unit Counting
Allergy skin tests are billed one unit per test, so a 40-allergen prick panel on 95004 is 40 units, not one. Medicare's allergy testing billing guidance (LCD L36402) states this directly. Under-counting loses payment on every panel. Over-counting, or billing a panel size the chart doesn't support, is what draws an audit.
02
Biologic and IVIG Authorizations
Xolair, Nucala, Fasenra, Tezspire, and immune globulin usually need prior authorization, and approvals expire. A dose given one day after the approval lapses is a denied claim for a drug the practice already paid for.
03
95165 Dose Math
CPT and Medicare count a 95165 dose differently. CPT counts a dose as the antigens given in one injection from a multi-dose vial. Medicare counts a dose as 1 cc of extract and caps 95165 at 30 units per day. That means a 10 cc vial bills at most 10 doses to Medicare, however many injections it actually gives. In the proposed 2027 Physician Fee Schedule, CMS asked for comments on the dose definition and on replacing the 30-dose limit with an annual cap. The comment period closed September 14, 2026, so the rule may change for 2027.
04
Buy-and-Bill Biologics
A buy-and-bill biologic is paid in J-code units, not vials, and each code has its own unit size. Omalizumab (J2357) is billed per 5 mg. Mepolizumab (J2182), benralizumab (J0517), tezepelumab (J2356), and reslizumab (J2786) are billed per 1 mg. Medicare Part B also requires a waste modifier on single-dose containers. JW reports a discarded amount. JZ has been required since July 1, 2023 when nothing was discarded. A missing or wrong modifier can get the claim rejected.
05
Medical vs. Pharmacy Benefit Checks
The same patient can have skin testing and extract under the medical benefit and a biologic under the pharmacy benefit. Some plans pay a biologic through buy-and-bill, and others require a specialty pharmacy. If nobody checks which one applies before the first dose, the practice can end up holding a drug it can't bill.
06
Symptom-to-Test Documentation
Payers want every test and every extract tied to a documented history: the symptoms, the suspected allergens, prior treatment, and why this number of tests was needed. A note that lists 70 allergens with no clinical reason for the panel size invites a medical necessity denial.
07
Same-Day and Drug-Unit Denials
A separate E/M visit billed with testing or injections needs modifier 25 and its own documented work, and informed consent alone doesn't count as a separate visit. Medicare's LCD L36402 guidance also says allergy testing and immunotherapy aren't normally done on the same day, so reporting both on one date draws review. On the drug side, units that don't match the dose given get denied or reduced.
08
MUEs, LCDs, and Supervision Rules
Allergy billing runs under Medicare's medically unlikely edits (MUEs), such as the 30-unit daily cap on 95165. Local coverage determinations (LCDs) for allergy testing and the incident-to supervision rules also apply when staff give injections. HIPAA applies to every claim and record.
How Qualigenix Fixes Allergy and Immunology Gap
Qualigenix fixes each gap at the step where it starts, before the claim leaves the practice.
Test-Level Charge Capture
Our coders match the unit count on 95004, 95024, 95027, and the other testing codes to the tests recorded in the chart. Each test is billed one unit, and panel size is checked against the documented history.
Biologic Prior Authorization
We submit and track authorizations for Xolair, Nucala, Fasenra, Tezspire, and immune globulin. Approval end dates and dose counts are tracked, and renewals are filed before the next scheduled dose.
95165 Dose Tracking
We track 95165 doses per patient by payer: 1 cc per dose and 30 units per day for Medicare, and each commercial payer's own definition. If the 2027 final rule changes the Medicare limit, we update the tracking to match.
J-Code and JW/JZ Review
Every drug claim is checked for the right J-code, units that match the milligrams given, the NDC, and the JW or JZ modifier on single-dose containers.
Benefit Checks Before the First Vial
We confirm coverage for testing, extract, and biologics before treatment starts. That includes whether a biologic runs under the medical benefit or a specialty pharmacy, and any per-year limits on tests or doses.
Medical Necessity Review
We review notes for the history and findings each payer needs to support the test panel, the extract, and the biologic. Gaps go back to the provider before the claim is sent, not after it's denied.
Denial Management and Appeals
Qualigenix overturns 79% of the denials it works, across 50,000 denials worked a month, with an appeal turnaround of under 9 days. Allergy denials are sorted by root cause (unit count, dose limit, authorization, modifier), so the fix goes into the front-end process as well as the appeal.
Compliance Monitoring
We check allergy claims against MUEs, the LCD that applies to your Medicare contractor, and payer drug policies. Qualigenix holds a 98.6% compliance/audit pass rate and works under HIPAA-compliant processes.
CASE STUDY 01
Allergy practice with a high-volume immunotherapy program
THE SITUATION
Dose counts for 95165 were incorrect, injections were billed with wrong counts, and payer per-dose caps were exceeded, generating denials and takebacks.
WHAT QUALIGENIX DID
Unit counting was standardized for antigen preparation and injections separately, and payer dose caps were built into the charge process.
Key Outcomes & Turnaround
16.0% to 5.0%Denial rate (%)
62.0% to 97.0%95165 unit accuracy (%)
$29,000Monthly revenue recovered ($)
Audited Practice Results
Allergy/immunology group with high skin and in-vitro testing volume
THE SITUATION
Test counts exceeded payer maximums, and diagnoses did not support the panels billed, so testing claims were denied or reduced.
WHAT QUALIGENIX DID
Testing counts were aligned to payer limits, supporting diagnoses were verified, and medically necessary extended panels were documented for appeal.
Key Outcomes & Turnaround
18.0% to 5.0%Testing denials (%)
67.0% to 92.0%First-pass approval (%)
$21,000Monthly revenue protected ($)
Audited Practice Results
Allergy practice administering high-cost biologics (e.g., asthma/urticaria)
THE SITUATION
Auths lacked step-therapy history and diagnosis specificity, and J-code units/administration were misreported on high-dollar biologic claims.
WHAT QUALIGENIX DID
A biologic auth workflow assembled step-therapy documentation and confirmed auth before administration, and drug units/administration were reconciled to the record.
Key Outcomes & Turnaround
12.0% to 2.0%Auth-related denials (%)
70.0% to 98.0%Biologic capture accuracy (%)
$48,000Monthly revenue protected ($)
Audited Practice Results
Allergy and Immunology Codes We Bill
Qualigenix codes the full allergy and immunology service mix, from skin testing through biologic infusion.
Skin Testing (95004–95028)
Percutaneous tests (95004), venom and drug skin tests (95017, 95018), and intradermal tests (95024, 95027, 95028). Each is billed one unit per test.
COMPLIANCE
Allergy Practices We Support
Qualigenix bills for allergy and immunology practices, asthma centers, immunotherapy clinics, infusion centers, pediatric allergy practices, academic allergy programs, and multi-specialty groups with an allergy service line.
0%
Audit Pass Rate
<0%
Variance Threshold
Why Allergists Choose Qualigenix
0%
Increased Revenue and Collections
0day
Reduced Administrative Burden
0%
Enhanced Compliance
0%
Improved Cash Flow
QUESTIONS BUYERS ASK
Allergy & Immunology Billing Services FAQ
Still weighing it? A quick call answers the cost and denial questions for your practice.
Qualigenix quotes allergy billing after a free review of your claim volume, payer mix, and how much of your revenue comes from biologics. Call 786-259-0231 to start the review.
Yes. Qualigenix submits and tracks prior authorizations for Xolair, Nucala, Fasenra, Tezspire, and immune globulin, and files renewals before the approval expires.
We add JW when part of a single-dose container is discarded and JZ when none is. Medicare Part B has required one or the other since July 1, 2023.
Yes. Qualigenix works existing AR along with new claims and has reduced days in A/R from 54 to 36. Most practices start with a free AR review.
For Medicare, a 10 cc multi-dose vial bills at most 10 doses of 95165, because Medicare counts a dose as 1 cc and caps 95165 at 30 units per day. Commercial payers may use the CPT definition instead, so we track doses by payer.
Yes, if the provider performs a separate, documented E/M service beyond the testing, billed with modifier 25. Informed consent alone doesn't support a separate visit.
Yes. Qualigenix is system-agnostic and has worked across 133 EMR/EHR platforms, so your team keeps its current software.
Qualigenix onboards practices in 6 days on average.